Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

EBETOL groups. Dose reductions due to adverse reactions occurred in 42 percent of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34 percent of those receiving INTRON A/REBETOL.

REBETOL should not be used in patients with creatinine clearance less than 50 mL/min.

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's strategy regarding and the potential of PEGINTRON, REBETOL and boceprevir (SCH 503034). Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward- looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item 1A, "Ri
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
(Date:11/25/2009)... Reportlinker.com announces that a...talogue: ,, Pain Management - Global Trends ...Management---Global-Trends.html ,, Widespread ...anagement clinics, and the advent of new drugs hav...ement market. Healthcare reforms and reimbursement...
(Date:11/25/2009)... SYDNEY, Nov. 25 HeartWa... a leading innovator and provider of less invasive...volutionizing the treatment of advanced heart fail...an investor presentation at the 21st Annual Piper ...ednesday, December 2, 2009. The conference is bein...
(Date:11/24/2009)...RNewswire/ -- ,, WHAT: Rom Houbens, a Belgian...lowing an auto accident, was actually fully consci... of a Good Morning America segment. The DynaVox E...w people with Locked-in Syndrome and other conditi...rning America -- Tuesday, November 24 available ...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Demi Lovato Joins National Bullying Prevention Movement 53681 1Demi Lovato Joins National Bullying Prevention Movement 53681 2Abnormal Brain Circuits May Prevent Movement Disorder 53678 1Abnormal Brain Circuits May Prevent Movement Disorder 53678 2Abnormal Brain Circuits May Prevent Movement Disorder 53678 3Abnormal Brain Circuits May Prevent Movement Disorder 53678 4Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient 13365 1Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient 13365 2
..., exenatide offered added benefits of, weight los...etformin --, AMSTERDAM, Netherlands, Sept. 21 Am...i Lilly and Company (NYSE: LLY ),today announced ...ection,with insulin glargine on beta-cell function...2 diabetes. Study findings showed one year of exen...
...atients at Beaumont,Hospitals are the first in the...adiation therapy that is painless, faster, more ac...t doctors and physicists invented and patented the...hine is manufactured in,England by Elekta, which i...s treated on Sept. 10. The painless treatment tak...
Other Medicine Technology:One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 2One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 3One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 4One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 5One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 6One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 7Beaumont Patients 1st to get Next Generation of Radiation Treatment 2
(Date:11/27/2009)..., , SAN FRANCISCO, Nov. 27 /PRNewswire-FirstC...announced that Blair Lambert, CFO/COO, will presen...ill be held at the May Fair Hotel in London, Engla...GMT. ,, To listen to a live broadcast of The Gy...t, please log on to www.gymboree.com, click on "Ou...
(Date:11/27/2009)..., , KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewswi...daq: SHMR ) ( "Shamir" ), a leading provider of i...c lens market, announced today that its board of d...n aggregate amount of US$ 10 million (approximatel... representative rate of exchange), or approximatel...
(Date:11/27/2009)...aring rates to bring unprecedented medical, econom...ov. 27 (HealthDay News) -- The number of people wi...uble over the next 25 years, a new study predicts....44.1 million people with the disease, up from 23.7...f treating people with diabetes will triple, the s...
(Date:11/27/2009)... Multi-purpose bilingual co...esigned for use by the business community to educa...y of subjects from Safety issues to Dinosuars to A... Saint Louis, MO (PRWEB) November 27, 200...lectronics or toys to keep them busy any hour of t...
(Date:11/26/2009)..., , NEW YORK, Nov. 27 With c...an ever to employ good practices to control the sp...ed to be proactive not only to keep ourselves heal...ck," said Eileen Finerty, RN, MS, CIC (certified i...on control and occupational health at Hospital for...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...ood and Drug Administration (FDA) are discussing h...t possible to collect better data about experiment...quirements. , Researchers from the National Insti...efore an audience of their peers on November 28-29...
...stitute for Brain Research will head an ambitious ...lexia, supported by a $8.5M grant from the Ellison...nwisher and John Gabrieli, are prominent experts i...cial interactions and communication, and affected ...
...X:,ROG.VX; RO.S; OTCQX; RHHBY) announced today tha...antitrust laws, it is not aware of any such law,th...ares tendered pursuant,to its outstanding Offer to..., Roche intends to accept for payment Ventana,shar...
...nc.,(Nasdaq: ABAX ), a medical products company m... today reported financial results for the fiscal,q...r the third quarter of fiscal 2008 include:, -- ...ble quarter. -- Piccolo instrument sales of 238 ...
...euticals, Inc. (OTC Bulletin Board: ACPH) is pleas... approved the Company,s application to,list its co...Q"). The,Company,s common stock will commence trad...ading on NASDAQ," stated Andy Reddick, the Company...
...s AmeriHealth Mercy,s product offerin...A, Jan. 31 The AmeriHealth Mercy Family of,Compan...ounced today that,it has acquired Community Behavi...now a wholly owned subsidiary of,AmeriHealth Mercy...
Other Medicine News:Health News:Researchers query FDA about updating requirements for drug approval 2Health News:MIT's McGovern Institute researchers awarded $8.5M to study brain basis of autism and dyslexia 2Health News:Roche Plans to Complete Ventana Offer on February 7th 2Health News:Roche Plans to Complete Ventana Offer on February 7th 3Health News:Roche Plans to Complete Ventana Offer on February 7th 4Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 2Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 3Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 4Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 5Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 6Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 7Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 8Health News:Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008 9Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2Health News:AmeriHealth Mercy Family of Companies Acquires Community Behavioral HealthCare Network of Pennsylvania 2
6.00mm Open Trephine Handle
5.50mm Open Trephine Handle
5.00mm Open Trephine Handle
Adjustable Troutman Trephine Handle, Fits 7mm - 9mm trephines
Medicine Products: